Learn what xanomeline-trospium is, how its muscarinic M1/M4 receptor mechanism differs from dopamine-based antipsychotics, and review key phase 2 clinical trial data for schizophrenia and Alzheimer’s-related psychosis.
- admin@condrug.com
- Mon - Sat: 8.00 am - 7.00 pm
We develop solutions for your clinical data needs